Reprogramming the tumor microenvironment with biotechnology
Open Access
- 31 January 2023
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 27 (1) , 1-23
Abstract
The tumor microenvironment (TME) is a unique environment that is developed by the tumor and controlled by tumor-induced interactions with host cells during tumor progression. The TME includes immune cells, which can be classified into two types: tumor- antagonizing and tumor-promoting immune cells. Increasing the tumor treatment responses is associated with the tumor immune microenvironment. Targeting the TME has become a popular topic in research, which includes polarizing macrophage phenotype 2 into macrophage phenotype 1 using Toll-like receptor agonists with cytokines, anti-CD47, and anti-SIPRα. Moreover, inhibiting regulatory T cells through blockades and depletion restricts immunosuppressive cells in the TME. Reprogramming T cell infiltration and T cell exhaustion improves tumor infiltrating lymphocytes, such as CD8 + or CD4 + T cells. Targeting metabolic pathways, including glucose, lipid, and amino acid metabolisms, can suppress tumor growth by restricting the absorption of nutrients and adenosine triphosphate energy into tumor cells. In conclusion, these TME reprogramming strategies exhibit more effective responses using combination treatments, biomaterials, and nanoparticles. This review highlights how biomaterials and immunotherapy can reprogram TME and improve the immune activity.Keywords
Funding Information
- National Research Foundation of Korea (2021RIS-001, 2019R1A4A1028700, 2022R1A4A2000776)
- Ministry of Health and Welfare (2021M3E5E5096420)
This publication has 142 references indexed in Scilit:
- Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challengesJournal of Hematology & Oncology, 2013
- Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cellsVirology Journal, 2012
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Glutamine addiction: a new therapeutic target in cancerTrends in Biochemical Sciences, 2010
- T‐cell exhaustion: characteristics, causes and conversionImmunology, 2010
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004
- Inflammation and cancerNature, 2002